Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios
作者： Giuseppe Aprile , Karim Rihawi , Mario Scartozzi , Roberto Bordonaro
DOI: 10.2217/FON.15.213
关键词: Oncology 、 Colorectal cancer 、 Advanced colorectal cancer 、 EGFR inhibitors 、 Internal medicine 、 Medicine 、 Translational research 、 Bioinformatics
摘要:
core.ac.uk
futuremedicine.com
sci-hub.se 参考文章(22)
, Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis BMJ. ,vol. 321, pp. 531- 535 ,(2000) , 10.1136/BMJ.321.7260.531
Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu, None, Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 372, pp. 1909- 1919 ,(2015) , 10.1056/NEJMOA1414325
Karim Rihawi, Riccardo Giampieri, Mario Scartozzi, Valeria Pusceddu, Marta Bonotto, Gianpiero Fasola, Stefano Cascinu, Giuseppe Aprile, Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer Expert Opinion on Investigational Drugs. ,vol. 24, pp. 1185- 1198 ,(2015) , 10.1517/13543784.2015.1054479
J. Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, Axel Grothey, Scott Kopetz, Alan Rong, Kelly S. Oliner, Roger Sidhu, Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews. ,vol. 41, pp. 653- 659 ,(2015) , 10.1016/J.CTRV.2015.05.008
A P Venook, M J Egorin, G L Rosner, T D Brown, T M Jahan, G Batist, R Hohl, D Budman, M J Ratain, C M Kearns, R L Schilsky, Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. Journal of Clinical Oncology. ,vol. 16, pp. 1811- 1819 ,(1998) , 10.1200/JCO.1998.16.5.1811
Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Diaz, Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra D. Eyring, Andrew D. Skora, Brandon S. Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency The New England Journal of Medicine. ,vol. 372, pp. 2509- 2520 ,(2015) , 10.1056/NEJMOA1500596
Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, Domenico Amoroso, Silvana Chiara, Chiara Carlomagno, Corrado Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone, Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 371, pp. 1609- 1618 ,(2014) , 10.1056/NEJMOA1403108
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4
Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S Oliner, Michael Wolf, Jennifer Gansert, None, Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Journal of Clinical Oncology. ,vol. 28, pp. 4697- 4705 ,(2010) , 10.1200/JCO.2009.27.4860
Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, Gianluca Masi, Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest Journal of Clinical Oncology. ,vol. 25, pp. 1670- 1676 ,(2007) , 10.1200/JCO.2006.09.0928